ABB Labs has added Avulux Migraine and Light Sensitivity lenses to its portfolio of lens designs, according to a press release. The lenses use a multiband precision optical filter that blocks up to 97% of harmful blue, amber, and red light while allowing soothing green light to pass through. In a 2020 double-blind, randomized, placebo-controlled trial, the lenses achieved both clinical and statistical significance compared with a clear placebo lens. The study was conducted by an independent clinical research organization.

Eyecare providers who are interested in offering Avulux through ABB can visit ecp.avulux.com/abb for details. OM